Literature DB >> 19500328

Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?

Esther W de Bekker-Grob1, Madelon N M van der Aa, Ellen C Zwarthoff, Marinus J C Eijkemans, Bas W van Rhijn, Theo H van der Kwast, Ewout W Steyerberg.   

Abstract

OBJECTIVE To determine how good microsatellite analysis (MA) markers in voided urine samples should be to make a surveillance procedure cost-effective in which cystoscopy is partly replaced by MA for patients with non-muscle-invasive urothelial carcinoma (NMI-UC). PATIENTS AND METHODS We constructed a semi-Markov model with a time horizon of 2 years, and a man aged 65 years as reference case. Data were used from a randomized trial (including 448 patients with NMI-UC from 10 hospitals), and from other data sources. The costs and effects (probability of being in a specific health state) were compared for two surveillance strategies: (i) cystoscopy of the urinary bladder every 3 months (conventional arm), and (ii) semi-automated MA of voided urine samples to identify loss of heterozygosity every 3 months, with a control cystoscopy at 3, 12 and 24 months (test arm). Various sensitivity analyses were used to determine the sensitivity, specificity, and costs of MA of urine for which the test arm was as cost-effective as the conventional arm. RESULTS The probability of being without recurrence after 2 years of surveillance was similar (86.6% conventional arm vs 86.3% test arm) with currently available MA markers (sensitivity of 58% and specificity of 73%). However, the test arm led to higher costs ($4104 vs $3433 per head). The test arm would be as effective and cost the same as the conventional arm if the sensitivity of the currently available MA markers was increased at > or =61%, had a specificity of 73%, and decreased the costs of the MA test per follow-up sample from $158 to <$70. CONCLUSIONS Over 2 years, surveillance in which cystoscopy is partly replaced by currently available urinary MA to reduce patient burden can only provide a cost-effective alternative to the conventional surveillance if the MA urine test had a slightly higher sensitivity and its costs could be reduced.

Entities:  

Mesh:

Year:  2008        PMID: 19500328     DOI: 10.1111/j.1464-410X.2008.08323.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  11 in total

1.  Testis expressed 19 is a novel cancer-testis antigen expressed in bladder cancer.

Authors:  Jianhua Zhong; Yan Chen; Xinhui Liao; Jiaqiang Li; Han Wang; Chenglong Wu; Xiaowen Zou; Gang Yang; Jing Shi; Liya Luo; Litao Liu; Jianping Deng; Aifa Tang
Journal:  Tumour Biol       Date:  2015-12-22

2.  Usefulness of urine cytology as a routine work-up in the detection of recurrence in patients with prior non-muscle-invasive bladder cancer: practicality and cost-effectiveness.

Authors:  Bong Gi Ok; Yoon Seob Ji; Young Hwii Ko; Phil Hyun Song
Journal:  Korean J Urol       Date:  2014-10-10

Review 3.  The health economics of bladder cancer: an updated review of the published literature.

Authors:  Christina Yeung; Tuan Dinh; Joseph Lee
Journal:  Pharmacoeconomics       Date:  2014-11       Impact factor: 4.981

4.  Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer.

Authors:  Eveline A M Heijnsdijk; Daan Nieboer; Tullika Garg; Iris Lansdorp-Vogelaar; Harry J de Koning; Matthew E Nielsen
Journal:  BJU Int       Date:  2018-08-27       Impact factor: 5.588

5.  Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.

Authors:  David D'Andrea; Francesco Soria; Sonja Zehetmayer; Kilian M Gust; Stephan Korn; J Alfred Witjes; Shahrokh F Shariat
Journal:  BJU Int       Date:  2019-02-05       Impact factor: 5.588

Review 6.  Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews.

Authors:  Lauren J Lee; Christina S Kwon; Anna Forsythe; Carla M Mamolo; Elizabeth T Masters; Ira A Jacobs
Journal:  Clinicoecon Outcomes Res       Date:  2020-11-23

Review 7.  Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions.

Authors:  Chulso Moon; Maxie Gordon; David Moon; Thomas Reynolds
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

Review 8.  The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know?

Authors:  Rafaela Malinaric; Guglielmo Mantica; Lorenzo Lo Monaco; Federico Mariano; Rosario Leonardi; Alchiede Simonato; André Van der Merwe; Carlo Terrone
Journal:  Int J Environ Res Public Health       Date:  2022-08-05       Impact factor: 4.614

9.  Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood.

Authors:  Angela A G van Tilborg; Lucie C Kompier; Irene Lurkin; Ricardo Poort; Samira El Bouazzaoui; Kirstin van der Keur; Tahlita Zuiverloon; Lars Dyrskjot; Torben F Orntoft; Monique J Roobol; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

10.  An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer.

Authors:  Madhusudan Koya; Sue Osborne; Christophe Chemaslé; Sima Porten; Anne Schuckman; Andrew Kennedy-Smith
Journal:  BMC Urol       Date:  2020-02-11       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.